Easton Pharmaceuticals Inc banner

Easton Pharmaceuticals Inc
OTC:EAPH

Watchlist Manager
Easton Pharmaceuticals Inc Logo
Easton Pharmaceuticals Inc
OTC:EAPH
Watchlist
Price: 0 USD Market Closed
Market Cap: $0

Easton Pharmaceuticals Inc
Investor Relations

Easton Pharmaceuticals, Inc. engages in the design, development, and marketing of drugs, therapeutic, and cosmetic healthcare products. The company is headquartered in North York, Ontario. The company went IPO on 2000-09-29. The firm has a transdermal delivery technology (Viorra Delivery Matrix or VDM), which is incorporated in a line of therapeutic over-the-counter (OTC) products. The firm owns topically-delivered drugs and therapeutic/cosmetic healthcare products focused on cancer and other health problems geared towards female sexual dysfunction, wound healing, pain, motion sickness and other conditions. The firm's products are in various stages of commercialization. The firm's products include Nauseasol, which is a motion sickness gel; Skin Renou HA, which is an anti-aging wrinkle cream; Kenestrin Gel, which is a is a pain relief gel; Viorra, which serves as an aid to the relief of female sexual arousal disorder (FSAD); XILIVE, which is an early-stage cancer drug, and FSAD) drug, which includes a water-based complex polymer matrix.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Mr. Evan Karras
CEO, President, Secretary, Treasurer, CFO & Director
No Bio Available
Dr. Lilla Albert Ph.D.
Chief Marketing and Technology Officer
No Bio Available
Ms. Elena Milantoni
Director of Finance and Administration
No Bio Available
Mr. Neil Mellor
Senior Business Consultant, Special Advisor and Member of Advisory Board
No Bio Available

Contacts

Address
ONTARIO
North York
Suite 200, 265 Rimrock Road
Contacts
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett